Literature DB >> 28116779

Long-term dietary supplementation with low-dose nobiletin ameliorates hepatic steatosis, insulin resistance, and inflammation without altering fat mass in diet-induced obesity.

Young-Je Kim1, Myung-Sook Choi2, Je Tae Woo3, Mi Ji Jeong4, Sang Ryong Kim5, Un Ju Jung4.   

Abstract

SCOPE: We evaluated the long-term effect of low-dose nobiletin (NOB), a polymethoxylated flavone, on diet-induced obesity and related metabolic disturbances. METHODS AND
RESULTS: C57BL/6J mice were fed a high-fat diet (HFD, 45 kcal% fat) with or without NOB (0.02%, w/w) for 16 weeks. NOB did not alter food intake or body weight. Despite increases in fatty acid oxidation-related genes expression and enzymes activity in adipose tissue, NOB did not affect adipose tissue weight due to simultaneous increases in lipogenic genes expression and fatty acid synthase activity. However, NOB significantly decreased not only pro-inflammatory genes expression in adipose tissue but also proinflammatory cytokine levels in plasma. NOB-supplemented mice also showed improved glucose tolerance and insulin resistance, along with decreased levels of plasma insulin, free fatty acids, total cholesterol, non-HDL-cholesterol, and apolipoprotein B. In addition, NOB caused significant decreases in hepatic lipid droplet accumulation and triglyceride content by activating hepatic fatty acid oxidation-related enzymes. Hepatic proinflammatory TNF-α mRNA expression, collagen accumulation, and plasma levels of aminotransferases, liver damage indicators, were also significantly lower in NOB-supplemented mice.
CONCLUSION: These findings suggest that long-term supplementation with low-dose NOB can protect against HFD-induced inflammation, insulin resistance, dyslipidemia, and nonalcoholic fatty liver disease, without ameliorating adiposity.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Fatty acid oxidation; Inflammation; Insulin resistance; Nobiletin; Nonalcoholic fatty liver disease

Mesh:

Substances:

Year:  2017        PMID: 28116779     DOI: 10.1002/mnfr.201600889

Source DB:  PubMed          Journal:  Mol Nutr Food Res        ISSN: 1613-4125            Impact factor:   5.914


  6 in total

Review 1.  Flavonoids from Aurantii Fructus Immaturus and Aurantii Fructus: promising phytomedicines for the treatment of liver diseases.

Authors:  Jianzhi Wu; Guangrui Huang; Yajing Li; Xiaojiaoyang Li
Journal:  Chin Med       Date:  2020-08-26       Impact factor: 5.455

Review 2.  Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application.

Authors:  Yu Xu; Wei Guo; Cheng Zhang; Feiyu Chen; Hor Yue Tan; Sha Li; Ning Wang; Yibin Feng
Journal:  Front Pharmacol       Date:  2020-05-12       Impact factor: 5.810

Review 3.  Role of Natural Phenolics in Hepatoprotection: A Mechanistic Review and Analysis of Regulatory Network of Associated Genes.

Authors:  Priyanka Saha; Anupam Das Talukdar; Rajat Nath; Satyajit D Sarker; Lutfun Nahar; Jagajjit Sahu; Manabendra Dutta Choudhury
Journal:  Front Pharmacol       Date:  2019-05-24       Impact factor: 5.810

4.  Anti-Obesity Natural Products Tested in Juvenile Zebrafish Obesogenic Tests and Mouse 3T3-L1 Adipogenesis Assays.

Authors:  Hiroko Nakayama; Kanae Hata; Izumi Matsuoka; Liqing Zang; Youngil Kim; Djongchi Chu; Lekh Raj Juneja; Norihiro Nishimura; Yasuhito Shimada
Journal:  Molecules       Date:  2020-12-10       Impact factor: 4.411

5.  A network pharmacology-based approach to explore the effects of Chaihu Shugan powder on a non-alcoholic fatty liver rat model through nuclear receptors.

Authors:  Huan Nie; Yuanjun Deng; Chuiyang Zheng; Maoxing Pan; Jiqian Xie; Yupei Zhang; Qinhe Yang
Journal:  J Cell Mol Med       Date:  2020-03-18       Impact factor: 5.310

6.  Efficacy of nobiletin in improving hypercholesterolemia and nonalcoholic fatty liver disease in high-cholesterol diet-fed mice.

Authors:  Young-Je Kim; Dae Seong Yoon; Un Ju Jung
Journal:  Nutr Res Pract       Date:  2021-03-11       Impact factor: 1.926

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.